Anest. intenziv. Med. 2014;25(5):367-372

New direct oral anticoagulants (NOAC) - solutions to potential problems with coagulation assessmentIntesive Care Medicine - Special Article

Kvasnička Jan*, Malíková Ivana
Trombotické centrum ÚLBLD Všeobecné fakultní nemocnice a 1. lékařské fakulty Univerzity Karlovy, Praha

An overview of the options for laboratory monitoring of the new oral anticoagulants (the direct Xa inhibitors rivaroxaban and apixaban and the direct thrombin inhibitor dabigatran), and selection of appropriate coagulation tests that can be used in clinical practice are presented.

Keywords: laboratory tests; rivaroxaban; apixaban; dabigatran; emergency medicine

Received: January 14, 2014; Accepted: July 2, 2014; Published: October 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kvasnička J, Malíková I. New direct oral anticoagulants (NOAC) - solutions to potential problems with coagulation assessment. Anest. intenziv. Med. 2014;25(5):367-372.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kvasnička, J., Hájková, J., Bobčíková, P. et al. Prevalence polymorfismů CYP2C9 a VKORC1 v České republice a zamyšlení nad výhledy antikolagulační léčby warfarinem. Cor et Vasa, 2011, 53, s. 522-526. Go to original source...
    2. Souhrn údajů o přípravku Xarelto [online]. [cit. 2013-12-18]. Dostupný na www: http://www.emea.europa.eu/docs/cs_CZ/document_library/EPAR_Product_Information/human/000944/WC500057108.pdf.
    3. Souhrn údajů o přípravku Eliquis. [online]. [cit. 2013-12-18]. Dostupný na www: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_Product_Information/human/002148/WC500107728.pdf.
    4. Souhrn údajů o přípravku Pradaxa. [online]. [cit. 2013-12-18]. Dostupný na www: http://www.emea.europa.eu/docs/cs_CZ/document_library/EPAR_Product_Information/human/000829/WC500041059.pdf.
    5. Ageno, W., Crowther, M., Baglin, T. et al. Selection and assessment of patients treated with the novel oral antikoagulant drugs: a recomendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 2012, 11, s. 177-179. Go to original source... Go to PubMed...
    6. Kozek-Langenecker, S. A., Afshari, A., Albaladejo, P. et al. Management of severe perioperative bleeding. European Journal of Anaesthesiology, 2013, 30, s. 270-382. Go to original source... Go to PubMed...
    7. van Veen, J. J., Smith, J., Kitchen, S., Makris, M. Normal prothrombin time in the presence of therapeutic levels of rivaroxaban. British Journal of Haematology, 2013, 160, s. 859-861. Go to original source... Go to PubMed...
    8. Tripodi, A., Chantarangkul, V., Guinet, C., Samama, M. M. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients. results of an in vitro study. Journal of Thrombosis and Haemostasis, 2011, 9, s. 226-228. Go to original source... Go to PubMed...
    9. Tsakiris, D. A., Alberio, L. A. et al. Quantifizierung von Rivaroxaban und Beeinflussung von Gerinnungstests bei Patienten mit Rivaroxaban (Xarelto®) [online]. [cit. 2013-12-18]. Dostupný na www: http://www.sgh-ssh.ch/upload/File/2012_11.10._Rivaroxaban_D.pdf.
    10. Baglin, T., Hillarp, A., Tripodi, A. et al. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 2013, 12, s. 756-760. Go to original source... Go to PubMed...
    11. Čihák, R., Haman, L., Táborský, M. Praktická doporučení European Heart Rhythm Association pro použití nových perorálních antikoagulancií u pacientů s nevalvulární fibrilací síní. Cor et Vasa, 2014, 56, s. 42-56. Go to original source...

    Return to the content


    Anesteziologie a intenzivní medicína

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.